About MSUD

About MSUD

Maple syrup urine disease (MSUD) is an inherited disorder characterized by impaired protein metabolism, specifically the branched-chain amino acids leucine, isoleucine, and valine. The condition gets its name from the distinctive sweet odor of urine and earwax in affected infants.

IMPORTANT: IF UNTREATED, MSUD CAN LEAD TO DEVELOPMENTAL DELAYS, SEIZURES, COMA, AND DEATH.

1 in 185,000
Global Incidence
1 in 380
Old Order Mennonite
1 in 26,000
Ashkenazi Jewish

MSUD is a rare disease, affecting an estimated 1 in 185,000 infants worldwide. While affecting any ethnicity, the disorder occurs much more frequently in certain ethnic groups, such as the Old Order Mennonite population with an estimated incidence of about 1 in 380 newborns, and the Ashkenazi Jewish population with an estimated incidence of 1 in 26,000 newborns.

MSUD Discovery Timeline

1954
First Description: MSUD was first described in medical literature.
1957
Metabolic Understanding: Identified as an error in branched-chain amino acid metabolism.
1960s
Life-Saving Formula: The metabolic formula was developed, allowing survival for the first time.
1960s-1970s
Newborn Screening:   Some states began adding MSUD to newborn screening programs, enabling early detection and treatment.

Treatment & Management

A specialized medical formula provides all essential nutrients with the exception of the branched-chain amino acids leucine, isoleucine, and valine. These amino acids must be added to the diet in the precise amounts needed for normal growth and development. A strict diet and careful medical monitoring is essential throughout the lifespan.

With proper care, individuals with MSUD now live relatively normal and productive lives.